Petrelintide Delivers Up to 10.7% Weight Loss in Zealand‑Roche Phase 2 Trial

Zealand Pharma's Roche-partnered amylin analog petrelintide achieved statistically significant weight loss versus placebo in a 493-person phase 2 obesity trial (Zupreme-1), with up to 10.7% mean weight reduction at 42 weeks and a tolerable safety profile (no vomiting at the maximally effective dose; mild GI adverse events); the results support moving toward phase 3 (Zupreme-2) and related combination studies, though some analysts question its potential impact in a crowded obesity market, and the stock fell on the news.